Literature DB >> 24987924

Gynecologic Cancer InterGroup (GCIG) consensus review for vulvovaginal melanomas.

Mario M Leitao1, Xi Cheng, Anne L Hamilton, Nadeem A Siddiqui, Ina Jurgenliemk-Schulz, Sven Mahner, Elisabeth Åvall-Lundqvist, Kidong Kim, Gilles Freyer.   

Abstract

Vulvovaginal melanomas are rare tumors that account for a small fraction of all vulvovaginal cancers. Biologically, they seem to be similar to mucosal and acral melanomas of other sites. There are limited data specific to vulvovaginal melanomas, especially regarding systemic therapies. Most treatment decisions are based on extrapolation from data regarding cutaneous melanomas of other sites. It is reasonable to follow already established guidelines from other professional groups and societies. Outcomes tend to be worse compared with cutaneous melanomas likely because of the later presentation and physical biological characteristics of these tumors.

Entities:  

Mesh:

Year:  2014        PMID: 24987924     DOI: 10.1097/IGC.0000000000000198

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  16 in total

1.  Primary Vaginal Melanoma, A Rare and Aggressive Entity. A Case Report and Review of the Literature.

Authors:  Emmanouil Kalampokas; Theodoros Kalampokas; Christos Damaskos
Journal:  In Vivo       Date:  2017-01-02       Impact factor: 2.155

Review 2.  Primary malignant melanomas of the female lower genital tract: clinicopathological characteristics and management.

Authors:  Dongying Wang; Tianmin Xu; He Zhu; Junxue Dong; Li Fu
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

3.  Female genitourinary tract melanoma: mutation analysis with clinicopathologic correlation: a single-institution experience.

Authors:  Ozlen Saglam; Syeda M H Naqvi; Yonghong Zhang; Tania Mesa; Jamie K Teer; Sean Yoder; Jae Lee; Jane Messina
Journal:  Melanoma Res       Date:  2018-12       Impact factor: 3.599

4.  Cancer of the vagina: 2021 update.

Authors:  Tracey S Adams; Linda J Rogers; Mauricio A Cuello
Journal:  Int J Gynaecol Obstet       Date:  2021-10       Impact factor: 4.447

5.  Talimogene Laherparepvec in Advanced Mucosal Melanoma of the Urethra Upon Primary Resistance on Immune Checkpoint Inhibition: A Case Report.

Authors:  Anne Fröhlich; Friederike Hoffmann; Dennis Niebel; Eva Egger; Guido M Kukuk; Marieta Toma; Judith Sirokay; Thomas Bieber; Jennifer Landsberg
Journal:  Front Oncol       Date:  2020-05-08       Impact factor: 6.244

6.  Boron neutron capture therapy for vulvar melanoma and genital extramammary Paget's disease with curative responses.

Authors:  Junichi Hiratsuka; Nobuhiko Kamitani; Ryo Tanaka; Eisaku Yoden; Ryuji Tokiya; Minoru Suzuki; Rolf F Barth; Koji Ono
Journal:  Cancer Commun (Lond)       Date:  2018-06-19

7.  Combined immunotherapy and radiation for treatment of mucosal melanomas of the lower genital tract.

Authors:  Maria B Schiavone; Vance Broach; Alexander N Shoushtari; Richard D Carvajal; Kaled Alektiar; Marisa A Kollmeier; Nadeem R Abu-Rustum; Mario M Leitao
Journal:  Gynecol Oncol Rep       Date:  2016-04-14

8.  Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer.

Authors:  Toshiaki Saito; Tsutomu Tabata; Hitoshi Ikushima; Hiroyuki Yanai; Hironori Tashiro; Hitoshi Niikura; Takeo Minaguchi; Toshinari Muramatsu; Tsukasa Baba; Wataru Yamagami; Kazuya Ariyoshi; Kimio Ushijima; Mikio Mikami; Satoru Nagase; Masanori Kaneuchi; Nobuo Yaegashi; Yasuhiro Udagawa; Hidetaka Katabuchi
Journal:  Int J Clin Oncol       Date:  2017-11-20       Impact factor: 3.402

9.  Vulvar malignancies: an interdisciplinary perspective.

Authors:  Christoph Wohlmuth; Iris Wohlmuth-Wieser
Journal:  J Dtsch Dermatol Ges       Date:  2019-12-12       Impact factor: 5.584

10.  Multiple metastases after surgery for a rare vulvar malignant melanoma combined with immunotherapy: a case report.

Authors:  Wenjing Li; Jingzhi Song; Yiming Sun; Zhumei Cui
Journal:  J Int Med Res       Date:  2020-11       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.